medigraphic.com

2004, Número 2

<< Anterior

Arch Cardiol Mex 2004; 74 (2)


Hipertensión arterial en México. Guías y recomendaciones para su detección, control y tratamiento

Rosas M, Pastelín G, Martínez RJ, Herrera-Acosta J, Attie F

Idioma: Español
Referencias bibliográficas: 89
Paginas: 134-157
Archivo PDF: 195.60 Kb.


FRAGMENTO

La urgente necesidad de atender de manera específica y práctica los principales problemas de salud pública en nuestro país, hace necesaria la participación de todas las entidades relacionadas con la salud de México. Datos epidemiológicos nacionales recientemente publicados,1,2 enfatizan y dan cifras preocupantes de la prevalencia de las enfermedades crónicas esenciales (ECEA). En general, se puede afirmar que la prevalencia de todas las ECEA, denotan un crecimiento porcentual importante, sobre todo cuando se comparan con las informadas en la Encuesta Nacional de Enfermedades Crónicas de 19931 (ENEC). Una grave consecuencia de este aumento en la prevalencia de ECEA, es el incremento exponencial en la tasa de sus complicaciones, ocupando ya, en la república mexicana, la primera causa de morbilidad y mortalidad del adulto entre 20 y 69 años.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Presentación

  2. Valles V, Arroyo P, Fernandez V, Herrera J, Kuri-Morales P, Olaiz G, Tapia-Conyer, R: The Mexican ministry of Health conducted a national survey of chronic disease in 1992-3. Hypertension 1999; 33: 1094.

  3. Velazquez-Monroy O, Rosas PM, Lara EA, Pastelin HG, Castillo C, Attie F, Tapia CR: Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Arch Cardiol Mex 2003; 73(1): 62-77.

  4. Guías de Hipertensión

  5. Mascie-Taylor CG, Karim E: The burden of chronic disease. Science 2003; 302: 1921-1922.

  6. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hans-Werner H, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto Jaakko, Vanuzzo D, Vescio F: Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289: 2363-2369.

  7. Valles V, Arroyo P, Fernandez V, Herrera J, Kuri-Morales P, Olaiz G, Tapia-Conyer R: The Mexican Ministry of Health conducted a national survey of chronic disease in 1992-3. Hypertension 1999; 33: 1094.

  8. Velazquez-Monroy O, Rosas PM, Lara EA, Pastelin HG, Castillo C, Attie F, Tapia Conyer R: Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Arch Cardiol Mex 2003; 73(1): 62-77.

  9. Shumei Meng, Cason GW, Gannon AW, Racusen LC, Manning RDJr: Oxidative Stress in Dahl Salt-Sensitive Hypertension. Hypertension 2003; 41: 1346-1352.

  10. National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.

  11. U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program. Available at: http://www.nhlbi.nih.gov/about/nhbpep/index.htm. Accessed March 5, 2003.

  12. Sheps SG, Roccella EJ: Reflections on the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Curr Hypertens Rep 1999; 1: 342-5.

  13. Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B: Mechanisms of Disease: Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension. N Engl J Med 2002; 346: 913-23.

  14. Roccella EJ, Kaplan NM: Interpretation and evaluation of clinical guidelines. In: Izzo JL Jr, Black HR, eds. Hypertension Primer. Dallas, TX: American Heart Association, 2003; 126: 126-7.

  15. Vasan RS, Larson MG, Leip EP, et al: Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: A cohort study. Lancet 2001; 358: 1682-6.

  16. Vasan RS, Beiser A, Seshadri S, et al: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003-10.

  17. Lewington S, Clarke R, Qizilbash N, et al: Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.

  18. Rosas M: Arterial hypertension in Mexico and its association with other risk factors. Arch Cardiol Mex 2003; 73(Suppl 1): S137-40.

  19. Velasquez MO, Rosas PM, Lara EA, Pastelin HG, Attie F, Tapia CR: Grupo Encuesta Nacional de Salud 2000. Arterial hypertension in Mexico: results of the National Health Survey 2000. Arch Cardiol Mex 2002; 72(1): 71-84.

  20. Feinstein AR: Multivariable Analysis: An introduction. New Haven Connecticut: Yale University Press, 1996: 297-369.

  21. Himmelmman A, Kjldsen SE: Recent hypertension guidelines: JNC-7 and 2003 ESH/ESC. Blood Press 2003; 12(4): 196-7.

  22. Lohr KN: Rating the strength of scientific evidence: relevance for quality improvement programs. Int J Qual Health Care 2004; 16(1): 9-18.

  23. Feinstein AR: “Clinical Judgment” revisited: the distraction of quantitative models. Ann Intern Med 1994; 120: 799-805.

  24. World Hypertension League. Measuring your blood pressure. Available at: http://www.mco.edu/org/whl/bloodpre.html. Accessed April 1, 2003.

  25. Pickering T: Recommendations for the use of home (self) and ambulatory blood pressure monitoring. American Society of Hypertension Ad Hoc Panel. Am J Hypertens 1996; 9: 1-11.

  26. Verdecchia P: Prognostic value of ambulatory blood pressure: current evidence and clinical implications. Hypertension 2000; 35: 844-51.

  27. American Heart Association. Home monitoring of high blood pressure. Available at: http://www.americanheart.org/presenter.jhtml? identifier=576. Accessed April 1, 2003.

  28. Chobanian AV, Hill M: National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure: A critical review of current scientific evidence. Hypertension 2000; 35: 858-63.

  29. Karter Y, Curgunlu A, Altinisik S, Erturk N, Vehid S, Mihmanli I, Ayan F, Kutlu A, Arat A, Ozturk E, Erdine S: Target organ damage and changes in arterial compliance in white coat hypertension. Is white coat innocent? Blood Press 2003; 12(5-6): 307-13.

  30. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women. NEJM 2000; 342: 836-843.

  31. Backes JM: Role of C-reactive protein in cardiovascular disease. Ann Pharmacother 2004; 38(1): 110-8.

  32. Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y: Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord 2004; [Epub ahead of print].

  33. Stuveling EM, Bakker SJ, Hillege HL, Burgerhof JG, De Jong PE, Gans RO, De Zeeuw D: C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria. Hypertension 2004; [Epub ahead of print].

  34. Miyazaki M: Angiotensin II in organ organopathy. Nippon Rinsho 2004; 62(1): 21-7.

  35. Parrinello G, Colomba D, Bologna P, Licata A, Pinto A, Paterna S, Scaglione R, Licata G: Early carotid atherosclerosis and cardiac diastolyc abnormalities in hypertensive subjects. J Hum Hypertens 2004; 18(3): 201-5.

  36. Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L: Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points. Semin Nephrol 2004; 24(2): 147-57.

  37. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.

  38. Tsang TS, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, Seward JB: Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. J Am Coll Cardiol 2003; 42(7): 1199-205.

  39. Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlof B: Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study. Am J Hypertens 2001; 14(8 Pt 1): 775-82.

  40. Eren M, Gorgulu S, Uslu N, Celik S, Dagdeviren B, Tezel T: Relation between aortic stiffness and left ventricular diastolyc function in patients with hypertension, diabetes, or both. Heart 2004; 90(1): 37-43.

  41. Kern R, Szabo K, Hennerici M, Meairs S: Characterization of Carotid Artery Plaques Using Real-time Compound B-mode Ultrasound. Stroke 2004; [Epub ahead of print].

  42. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC: Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004; 109(9): 1089-94. Epub 2004 Mar 01.

  43. Fathi R, Haluska B, Isbel N, Short L, Marwick TH: The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 2004; 43(4): 616-23.

  44. Stehouwer CD: Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19(4): 778-81.

  45. Carreiro-Lewandowski E: Update on selected markers used in risk assessment for vascular disease. Clin Lab Sci 2004; 17(1): 43-9.

  46. Ruilope LM, Segura J, Campo C, Rodicio JL: Renal participation in cardiovascular risk in essential hypertension. Expert Rev Cardiovasc Ther 2003; 1(2): 309-315.

  47. Cockroft D, Gault MK: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

  48. Alderman M, Aiyer KJ: Uric acid: role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004; 20(3): 369-79.

  49. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41(6): 1183-90.

  50. Kanellis J, Nakagawa T, Herrera-Acosta J, Schreiner GF, Rodriguez-Iturbe B, Johnson RJ: A single pathway for the development of essential hypertension. Cardiol Rev 2003; 11(4): 180-96.

  51. Johnson RJ, Rodriguez-Iturbe B, Herrera-Acosta J: Nephron number and primary hypertension. N Engl J Med 2003; 348(17): 1717-9.

  52. Klein R, Klein BE, Tomany SC, Wong TY: The relation of retinal microvascular characteristics to age-related eye disease: the Beaver Dam eye study. Am J Ophthalmol 2004; 137(3): 435-44.

  53. Wong TY: Is retinal photography useful in the measurement of stroke risk? Lancet Neurol 2004; 3(3): 179-83.

  54. Dahlof B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC: Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004; [Epub ahead of print].

  55. Sidorenko BA, Preobrazhenskii DV, Soplevenko AV, Ivanova NA, Stetsenko TM: Candesartan - a Novel AT(1)-Angiotensin Receptor Blocker: Peculiarities of Pharmacology and Experience of Use in Arterial Hypertension Kardiologiia. 2004; 44(1): 55-65.

  56. Demaerschalk BM: Diagnosis and management of stroke (brain attack). Semin Neurol 2003; 23(3): 241-52.

  57. Cusi D, Barlassina C, Taglietti MV: Genetics of human arterial hypertension. J Nephrol 2003; 16(4): 609-15.

  58. Touyz RM, Schiffrin EL: Role of endothelin in human hypertension. Can J Physiol Pharmacol 2003; 81(6): 533-41.

  59. Weinberger MH: Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans. J Clin Hypertens 2002; 4: 274-6.

  60. Manning RD Jr, Hu L, Tan DY, Meng S. Role of abnormal nitric oxide systems in salt-sensitive hypertension. Am J Hypertens 2001; 14(6 Pt 2): 68S-73S.

  61. Lucas CP, Estigarribia JA, Darga LL, Reaven GM: Insulin and blood pressure in obesity. Hypertension 1985; 7: 702-706.

  62. Modan M, Halkin H, Almog S, Lusky A, Eshkil A, Shefi M, Shitrit A, Fuchs A: Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-817.

  63. Ferrannini E, Buzzigoli G, Bonadona R: Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.

  64. Shen D-C, Shieh S-M, Fuh M, Wu D-A, Chen Y-DI, Reaven GM: Resistance to insulin-stimulated glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988; 66: 580-583.

  65. Swislocki ALM, Hoffman BB, Reaven GM: Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419-423.

  66. Pollare T, Lithell H, Berne C: Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39: 167-174.

  67. Mbanya JC, Wilkinson R, Thomas T, Alberti K, Taylor R: Hypertension and hyperinsulinemia: a relation in diabetes but not in essential hypertension. Lancet 1988; I: 733-734.

  68. Collins VR, Dowse GK, Finch CF, Zimmet PZ: An inconsistent relationship between insulin and blood pressure in three Pacific Island populations. J Clin Epidemiol 1990; 43: 1369-1378.

  69. Saad MF, Lillioja S, Nyomba BL, Castillo C, Ferraro R, DeGregorio M, Ravussin E, Knowler WC, Bennett PH, Havard VV, Bogardus C: Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991; 324: 733-739.

  70. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Järvinen H: For the European Group for the Study of Insulin Resistance (EGIR) Insulin resistance, hyperinsulinemia, and blood pressure. Role of age and obesity. Hypertension 1992; 30: 1144-1149.

  71. Marigliano A, Tedde R, Sechi LA, Para A, Pisanu G, Pacifico A: Insulinemia and blood pressure: relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment. Am J Hypertens 1990; 3: 521-526.

  72. Shamiss A, Carroll J, Rosenthall T: Insulin resistance in secondary hypertension. Am J Hypertens 1992; 5: 26-28.

  73. Ferrari P, Weidmann P, Shaw S, Giachino D, Riesen W, Allemann Y, Heynen G: Altered insulin sensitivity, hyperinsulinemia and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589-596.

  74. Facchini F, Chen Y-DI, Clinkingbeard C, Jeppesen J, Reaven GM: Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens 1992; 5: 694-699.

  75. Allemann Y, Horber FF, Colombo M, Ferrari P, Shaw S, Jaeger P, Weidman P: Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. Lancet 1993; 341: 327-331.

  76. Ohno Y, Suzuki H, Yamakawa H, Nakamura M, Otsuka K, Saruta T: Impaired insulin sensitivity in young, lean normotensive offspring of essential hypertensive: possible role of disturbed calcium metabolism. J Hypertens 1993; 11: 421-426.

  77. Beatty OL, Harper R, Sheridan B, Atkinson AB, Bell PM: Insulin resistance in offspring of hypertensive parents. BMJ 1993; 307: 92-96.

  78. Skarfors ET, Lithell HO, Selinus I: Risk factors for the development of hypertension: a 10-year longitudinal study in middle-aged men. J Hypertens 1991; 9: 217-223.

  79. Lissner L, Bengtsson C, Lapidus L, Kristjansson K, Wedel H: Fasting insulin in relation to subsequent blood pressure changes and hypertension in women. Hypertension 1992; 20: 797-801.

  80. Taittonen L, Uhari M, Nuutinen M, Turtinen J, Pokka T, Akerblom HK: Insulin and blood pressure among healthy children. Am J Hypertens 1996; 9: 193-199.

  81. Raitakari OT, Porkka KVK, Rönnemaa T, Knip M, Uhari M, Akerblom HK, Viikari JSA: The role of insulin in clustering of serum lipids and blood pressure in children and adolescents. Diabetologia 1995; 38: 1042-1050.

  82. Zavaroni I, Bonini L, Gasparini P, Barilli AL, Zuccarelli A, Dall’Aglio E, Delsignore R, Reaven GM: Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla factory revisited. Metabolism 1994; 48: 989-994.

  83. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Asyndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000; 152: 908-911.

  84. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM: Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy, nondiabetic volunteers. Diabetes Care 2000; 23: 171-175.

  85. Reaven GM: Insulin Resistance/Compensatory Hyperinsulinemia, Essential Hypertension, and Cardiovascular Disease. J Clin Endocrinol Metab 2003; 88: 2399-2403.

  86. Mancia G, Mark AL: Arterial baroreflexes in humans. In: Shepherd JT, Abboud FM, eds. Handbook of Physiology, Section 2: The Cardiovascular System. Bethesda, Md: American Physiological Society; 1983: 755-793.

  87. Mancia G, Grassi G, Ferrari AU: Reflex control of the circulation in experimental and human hypertension. In: Zanchetti A, Mancia G, eds. Handbook of Hypertension, Vol 17: Pathophysiology of Hypertension. Amsterdam, Netherlands: Elsevier Science; 1997: 568-601.

  88. Collidge TA, Lammie GA, Fleming S, Mullins JJ: The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations. Prog Biophys Mol Biol 2004; 84: 301-19.

  89. Tuncel M, Ram VC: Hypertensive emergencies: etiology and management. Am J Cardiovasc Drugs 2003; 3: 21-31.




2020     |     www.medigraphic.com